What is the Projected CAGR value of the Secondary Hyperparathyroidism Treatment Market ?
Secondary Hyperparathyroidism Treatment Market is expected to grow at a CAGR of 9.2% during the forecast period 2023-2030.
Who are the key players in Secondary Hyperparathyroidism Treatment Market ?
Major players are Amgen Inc, Tairui Biotechnology Co Ltd, Sanofi SA, Validus Pharmaceuticals LLC, AbbVie Inc, ONO PHARMACEUTICAL CO LTD, Kyowa Kirin Co Ltd., Teva Pharmaceuticals USA, Inc and Pharmanovia.